Riskpilot← Back to searchSign inGet full accessSTARKEY NORWAY AS
ASActiveOrg 975825337Auglendsdalen 81, 4017 StavangerWholesale of pharmaceutical and medical goods · NACE 4646Est. 199511 employees
Revenue 2024
NOK 39,1M
+10% vs 2023
EBITDA margin
9.4%
+316% vs 2023
Equity ratio
71.4%
Financial strength
Net profit 2024
NOK 2,6M
+522% vs 2023
| Revenue | NOK 39,1M | +10% |
| EBITDA | NOK 3,7M | +316% |
| Net profit | NOK 2,6M | +522% |
| Total assets | NOK 17,9M | -4% |
| Equity | NOK 12,8M | +25% |
| Employees | 11 | — |
Legal name
STARKEY NORWAY AS
Org number
975825337
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
20. oktober 1995
Share capital
NOK 600 000
Employees
11 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og daglig leder hver for seg.
Address
Auglendsdalen 81, 4017 Stavanger
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 20 312 | 38 344 | 41 863 | 35 483 | 39 124 |
| Staff expenses | −7 242 | −9 839 | −10 078 | −10 702 | −9 133 |
| EBITDA | 3 012 | 1 914 | 2 597 | 879 | 3 660 |
| Depreciation & amort. | −93 | −87 | −189 | −340 | −365 |
| EBIT | 2 919 | 1 827 | 2 408 | 540 | 3 295 |
| Net financials | −98 | −50 | −5 | −5 | 5 |
| Profit before tax | 2 821 | 1 777 | 2 403 | 535 | 3 300 |
| Tax | 625 | 405 | 539 | 123 | 734 |
| Net profit | 2 196 | 1 372 | 1 864 | 412 | 2 565 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 14 780 | 19 657 | 23 064 | 18 754 | 17 945 |
| Equity | 6 591 | 7 963 | 9 827 | 10 239 | 12 805 |
| Long-term debt | 3 100 | 0 | 0 | 0 | 0 |
| Short-term debt | 5 089 | 11 694 | 13 237 | 8 515 | 5 141 |
| Total debt | 8 189 | 11 694 | 13 237 | 8 515 | 5 141 |
EBITDA margin
9.4%
This company
15.8%
Market median
-41% vs market
20202024
Equity ratio
71.4%
This company
38.2%
Market median
+87% vs market
20202024
Return on equity
20.0%
This company
18.4%
Market median
+9% vs market
20202024
Net profit margin
6.6%
This company
8.1%
Market median
-19% vs market
20202024
Asset turnover
2.18×
This company
1.12×
Market median
+95% vs market
20202024
Debt / equity
0.40×
This company
0.62×
Market median
+35% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
TQ Chief Executive Officer | Chief Executive Officer | 2025 |
| Former (1) | ||
YR Chief Executive Officer | Chief Executive Officer | 2012 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2019 | |
| Board of Directors | 2019 | |
| Board of Directors | 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Starkey Laboratories, Inc, Usa | Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of STARKEY NORWAY AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thorsten Quaas | Chief Executive Officer | 0 companies |
| Yngve Rye Saur | Chief Executive Officer | 0 companies |
| William Franklin Austin | Chairman | 0 companies |
| Brandon Lee Sawalich | Board of Directors | 0 companies |
| Paola Villa | Board of Directors | 0 companies |